Analysts expect Revance Therapeutics Inc (NASDAQ:RVNC) to post earnings per share of ($0.95) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Revance Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.90) and the lowest estimate coming in at ($0.98). Revance Therapeutics posted earnings of ($1.01) per share during the same quarter last year, which would indicate a positive year over year growth rate of 5.9%. The firm is scheduled to announce its next earnings report after the market closes on Thursday, November 1st.

According to Zacks, analysts expect that Revance Therapeutics will report full-year earnings of ($3.90) per share for the current financial year, with EPS estimates ranging from ($3.92) to ($3.89). For the next financial year, analysts expect that the business will report earnings of ($3.99) per share, with EPS estimates ranging from ($4.22) to ($3.71). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Revance Therapeutics.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.02). The company had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.93 million. Revance Therapeutics had a negative return on equity of 63.30% and a negative net margin of 13,690.62%.

A number of research analysts have recently commented on the stock. ValuEngine cut shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 27th. BidaskClub cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 15th. Cantor Fitzgerald restated a “buy” rating and issued a $50.00 price target on shares of Revance Therapeutics in a report on Friday, September 14th. JMP Securities cut shares of Revance Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, September 17th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Revance Therapeutics in a report on Monday, September 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. Revance Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $47.10.

Shares of NASDAQ RVNC traded down $0.32 during mid-day trading on Thursday, reaching $23.95. The company had a trading volume of 162,480 shares, compared to its average volume of 214,040. Revance Therapeutics has a 52 week low of $22.25 and a 52 week high of $37.45.

A number of institutional investors have recently modified their holdings of RVNC. BlackRock Inc. lifted its position in shares of Revance Therapeutics by 21.6% during the second quarter. BlackRock Inc. now owns 2,931,980 shares of the biopharmaceutical company’s stock valued at $80,482,000 after buying an additional 521,536 shares during the last quarter. Millennium Management LLC lifted its position in shares of Revance Therapeutics by 46.8% during the first quarter. Millennium Management LLC now owns 1,494,441 shares of the biopharmaceutical company’s stock valued at $46,029,000 after buying an additional 476,209 shares during the last quarter. Fosun International Ltd lifted its position in shares of Revance Therapeutics by 48.0% during the second quarter. Fosun International Ltd now owns 472,532 shares of the biopharmaceutical company’s stock valued at $12,971,000 after buying an additional 153,219 shares during the last quarter. Northern Trust Corp lifted its position in shares of Revance Therapeutics by 22.5% during the second quarter. Northern Trust Corp now owns 415,856 shares of the biopharmaceutical company’s stock valued at $11,415,000 after buying an additional 76,406 shares during the last quarter. Finally, OppenheimerFunds Inc. lifted its position in shares of Revance Therapeutics by 10.6% during the second quarter. OppenheimerFunds Inc. now owns 252,370 shares of the biopharmaceutical company’s stock valued at $6,927,000 after buying an additional 24,284 shares during the last quarter. Institutional investors own 94.30% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Featured Article: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on Revance Therapeutics (RVNC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.